Regulatory challenges in innovation and evaluation of extracorporeal membrane oxygenation:Database analysis and future perspectives  

作　　者：Guohui Jiao Yuji Wang Yulong Guan Xiaofan He Jingjing Miao Kun Wu Jingyu Chen Qingfeng Luo 

机构地区：[1]Center for Medical Device Evaluation,National Medical Products Administration,Beijing 100081,China [2]Department of Extracorporeal Circulation,Fuwai Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100037,China [3]Guangdong Medical Devices Quality Surveillance and Test Institute,NMPA Key Laboratory for Extracorporeal Circulation Devices,Guangzhou,Guangdong 510663,China [4]Wuxi Lung Transplant Center,Wuxi People’s Hospital Affiliated to Nanjing Medical University,Wuxi,Jiangsu 214023,China [5]Center for Lung Transplantation,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310052,China

出　　处：《Chinese Medical Journal》2024年第24期3139-3141,共3页中华医学杂志(英文版)

基　　金：supported by grants from Noncommunicable Chronic Diseases-National Science and Technology Major Project(No.2023YFC2507100);National Medical Products Administration Key Laboratory for Extracorporeal Circulation Devices:Open Project(No.2024YB01).

摘　　要：To the Editor:During the coronavirus disease 2019(COVID-19)pandemic,patients with severe respiratory failure required ventilators or even higher levels of life support,bringing extracorporeal membrane oxygenation(ECMO)into the spotlight.[1]ECMO is commonly used for the rescue and treatment of patients with severe cardiopulmonary failure;its core components are the membrane lung(oxygenator)and blood pump with two fundamental support modes:venovenous(V-V)and venoarterial(V-A)ECMO.COVID-19 patients may require V-V ECMO for acute respiratory distress syndrome and when combined cardio-circulatory support is needed;the support mode could be V-A ECMO.

关 键 词：RESPIRATORY DISTRESS EXTRACORPOREAL 

分 类 号：R65[医药卫生—外科学]